NL8020152A - Werkwijze ter bereiding van sterk gezuiverde protrom- bine-complexconcentraten, de aldus verkregen concen- traten en hun toepassing. - Google Patents
Werkwijze ter bereiding van sterk gezuiverde protrom- bine-complexconcentraten, de aldus verkregen concen- traten en hun toepassing. Download PDFInfo
- Publication number
- NL8020152A NL8020152A NL8020152A NL8020152A NL8020152A NL 8020152 A NL8020152 A NL 8020152A NL 8020152 A NL8020152 A NL 8020152A NL 8020152 A NL8020152 A NL 8020152A NL 8020152 A NL8020152 A NL 8020152A
- Authority
- NL
- Netherlands
- Prior art keywords
- prothrombin complex
- source
- process according
- iii
- elution
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 32
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000012141 concentrate Substances 0.000 title description 18
- 108010094028 Prothrombin Proteins 0.000 claims description 32
- 102100027378 Prothrombin Human genes 0.000 claims description 32
- 229940039716 prothrombin Drugs 0.000 claims description 32
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 24
- 229960002897 heparin Drugs 0.000 claims description 24
- 229920000669 heparin Polymers 0.000 claims description 24
- 238000010828 elution Methods 0.000 claims description 19
- 238000001179 sorption measurement Methods 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 8
- 239000003463 adsorbent Substances 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 229940024790 prothrombin complex concentrate Drugs 0.000 claims description 7
- 102000004411 Antithrombin III Human genes 0.000 claims description 5
- 108090000935 Antithrombin III Proteins 0.000 claims description 5
- 229960005348 antithrombin iii Drugs 0.000 claims description 5
- 230000015271 coagulation Effects 0.000 claims description 5
- 238000005345 coagulation Methods 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 239000004019 antithrombin Substances 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- 238000003197 gene knockdown Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 10
- 102100022641 Coagulation factor IX Human genes 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- 108010076282 Factor IX Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229960004222 factor ix Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000004023 fresh frozen plasma Substances 0.000 description 2
- 208000009429 hemophilia B Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- -1 DEAE ion Chemical class 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7911272 | 1979-05-04 | ||
| FR7911272A FR2472390A1 (fr) | 1979-05-04 | 1979-05-04 | Procede de preparation de concentres de complexe prothrombinique hautement purifies, et concentres obtenus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8020152A true NL8020152A (nl) | 1981-02-27 |
Family
ID=9225039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8020152A NL8020152A (nl) | 1979-05-04 | 1980-05-05 | Werkwijze ter bereiding van sterk gezuiverde protrom- bine-complexconcentraten, de aldus verkregen concen- traten en hun toepassing. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4465623A (en, 2012) |
| JP (1) | JPH0424360B2 (en, 2012) |
| AR (1) | AR227021A1 (en, 2012) |
| AT (1) | ATA903980A (en, 2012) |
| BE (1) | BE883096A (en, 2012) |
| CA (1) | CA1157375A (en, 2012) |
| CH (1) | CH654329A5 (en, 2012) |
| DE (1) | DE3043409C3 (en, 2012) |
| DK (1) | DK157169C (en, 2012) |
| ES (1) | ES491042A0 (en, 2012) |
| FR (1) | FR2472390A1 (en, 2012) |
| GB (1) | GB2061287B (en, 2012) |
| IT (1) | IT1131109B (en, 2012) |
| MX (1) | MX5960E (en, 2012) |
| NL (1) | NL8020152A (en, 2012) |
| NO (1) | NO155477C (en, 2012) |
| SE (1) | SE452250C (en, 2012) |
| WO (1) | WO1980002426A1 (en, 2012) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0044343B1 (en) * | 1980-01-28 | 1984-08-22 | Baxter Travenol Laboratories, Inc. | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions |
| US4663164A (en) * | 1980-01-28 | 1987-05-05 | Baxter Travenol Laboratories, Inc. | Aqueous compositions for treating blood clotting factor inhibitors |
| AT379310B (de) * | 1983-05-20 | 1985-12-27 | Immuno Ag | Verfahren zur herstellung eines antithrombin iii-heparin- bzw. antithrombin iii-heparinoidkonzentrates |
| US4786726A (en) * | 1986-01-06 | 1988-11-22 | Blood Systems, Inc. | Factor IX therapeutic blood product, means and methods of preparing same |
| DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
| DE3625090A1 (de) * | 1986-07-24 | 1988-01-28 | Behringwerke Ag | Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung |
| DE3727610A1 (de) * | 1987-08-19 | 1989-03-02 | Behringwerke Ag | Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung |
| US6541275B1 (en) | 1988-02-03 | 2003-04-01 | Dade Behring Inc. | Immunoassay for F1.2 prothrombin fragment |
| JPH0219400A (ja) * | 1988-07-07 | 1990-01-23 | Green Cross Corp:The | トロンビンまたはプロトロンビンの製造方法 |
| KR100330540B1 (ko) * | 1993-04-05 | 2002-09-04 | 웰파이드 코포레이션 | 안티트롬빈-iii액상제제및그안정화방법 |
| US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
| US6491965B1 (en) | 1995-11-30 | 2002-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US6562781B1 (en) | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US20080306610A1 (en) * | 2007-06-07 | 2008-12-11 | Zimmer Orthobiologics, Inc. | Tissue processing for nonimmunogenic implants |
| US8435305B2 (en) | 2010-08-31 | 2013-05-07 | Zimmer, Inc. | Osteochondral graft delivery device and uses thereof |
| USD843660S1 (en) | 2017-11-27 | 2019-03-19 | Mary Kay Inc. | Cosmetic compact |
| USD863685S1 (en) | 2017-11-27 | 2019-10-15 | Mary Kay Inc. | Cosmetic compact |
| USD850006S1 (en) | 2017-11-27 | 2019-05-28 | Mary Kay Inc. | Cosmetic compact |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2867567A (en) * | 1955-01-21 | 1959-01-06 | Nat Res Dev | Process of preparing anti-haemophilic globulin |
| US3560475A (en) * | 1969-06-19 | 1971-02-02 | Baxter Laboratories Inc | Prothrombin complex prepared by precipitation with polyethylene glycol |
| JPS5314604B2 (en, 2012) * | 1972-12-20 | 1978-05-18 | ||
| US4087415A (en) * | 1976-06-09 | 1978-05-02 | William L. Wilson | Antithrombin III |
| US4081432A (en) * | 1977-07-25 | 1978-03-28 | Monsanto Company | Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers |
| JPS6040859B2 (ja) * | 1977-07-27 | 1985-09-12 | 喜温 三浦 | 抗血栓性人工医療材料 |
| AT359646B (de) * | 1979-04-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung von nebenwirkungs- freien plasmafraktionen |
| DE3101752A1 (de) * | 1981-01-21 | 1982-08-26 | Behringwerke Ag, 3550 Marburg | "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen" |
-
1979
- 1979-05-04 FR FR7911272A patent/FR2472390A1/fr active Granted
-
1980
- 1980-04-30 ES ES491042A patent/ES491042A0/es active Granted
- 1980-05-02 IT IT21723/80A patent/IT1131109B/it active
- 1980-05-02 BE BE0/200456A patent/BE883096A/fr not_active IP Right Cessation
- 1980-05-02 CA CA000351182A patent/CA1157375A/fr not_active Expired
- 1980-05-05 WO PCT/FR1980/000069 patent/WO1980002426A1/fr active Application Filing
- 1980-05-05 NL NL8020152A patent/NL8020152A/nl active Search and Examination
- 1980-05-05 GB GB8040646A patent/GB2061287B/en not_active Expired
- 1980-05-05 AR AR280901A patent/AR227021A1/es active
- 1980-05-05 DE DE3043409T patent/DE3043409C3/de not_active Expired - Fee Related
- 1980-05-05 JP JP55500927A patent/JPH0424360B2/ja not_active Expired
- 1980-05-05 CH CH98/81A patent/CH654329A5/fr not_active IP Right Cessation
- 1980-05-05 AT AT0903980A patent/ATA903980A/de unknown
- 1980-05-06 MX MX808799U patent/MX5960E/es unknown
- 1980-12-29 SE SE8009157A patent/SE452250C/sv not_active IP Right Cessation
-
1981
- 1981-01-02 NO NO81810009A patent/NO155477C/no unknown
- 1981-01-02 DK DK001281A patent/DK157169C/da not_active IP Right Cessation
-
1983
- 1983-03-17 US US06/476,126 patent/US4465623A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK157169C (da) | 1990-04-23 |
| ES8100763A1 (es) | 1980-12-01 |
| BE883096A (fr) | 1980-11-03 |
| WO1980002426A1 (fr) | 1980-11-13 |
| DK1281A (da) | 1981-01-02 |
| FR2472390A1 (fr) | 1981-07-03 |
| NO810009L (no) | 1981-01-02 |
| AR227021A1 (es) | 1982-09-15 |
| NO155477B (no) | 1986-12-29 |
| GB2061287B (en) | 1983-09-14 |
| NO155477C (no) | 1987-04-08 |
| MX5960E (es) | 1984-09-06 |
| DK157169B (da) | 1989-11-20 |
| SE8009157L (sv) | 1980-12-29 |
| CH654329A5 (fr) | 1986-02-14 |
| FR2472390B1 (en, 2012) | 1983-07-08 |
| DE3043409C2 (en, 2012) | 1993-12-23 |
| US4465623A (en) | 1984-08-14 |
| CA1157375A (fr) | 1983-11-22 |
| SE452250B (sv) | 1987-11-23 |
| IT8021723A0 (it) | 1980-05-02 |
| SE452250C (sv) | 1998-04-06 |
| DE3043409C3 (de) | 1993-12-23 |
| IT1131109B (it) | 1986-06-18 |
| ATA903980A (de) | 1982-05-15 |
| DE3043409T1 (de) | 1982-02-18 |
| JPS56500569A (en, 2012) | 1981-04-30 |
| JPH0424360B2 (en, 2012) | 1992-04-24 |
| GB2061287A (en) | 1981-05-13 |
| ES491042A0 (es) | 1980-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8020152A (nl) | Werkwijze ter bereiding van sterk gezuiverde protrom- bine-complexconcentraten, de aldus verkregen concen- traten en hun toepassing. | |
| CA2201714C (en) | Method for isolation of highly pure von willebrand factor | |
| DK173859B1 (da) | Fremgangsmåde til fremstilling af et højrenset humant faktor IX koncentrat og andre plasmaproteiner | |
| US6924151B2 (en) | Stable factor VIII/vWF-complex | |
| US6465624B1 (en) | Purification of von-Willebrand factor by cation exchanger chromatography | |
| ES2281104T3 (es) | Proceso para separar el inhibidor de alfa-1-proteinasa de una pasta de fraccion cohn iv-1 + iv-4. | |
| EP0378208A2 (en) | Production method for protein-containing composition | |
| NO180741B (no) | Fremgangsmåte for isolering av Faktor VIII | |
| JPH10509144A (ja) | ▲ｖｉｉｉ▼因子の精製方法 | |
| EP0148843B1 (en) | A concentrate of the antihemophilic factor viii and a process for producing it | |
| US6579723B1 (en) | Method of recovering highly purified vWF or factor VIII/vWF-complex | |
| US4774323A (en) | Purification of von Willebrand Factor solutions using gel permeation chromatography | |
| US5097019A (en) | Pharmaceutical containing tissue protein pp4, a process for the preparation of pp4 and for the pasteurization thereof, and the use of pp4 | |
| EP0512883A1 (fr) | Concentré de facteur XI de la coagulation sanguine à haute activité spécifique, approprié à un usage thérapeutique et son procédé de préparation | |
| AU2003248466B2 (en) | Concentrate of a factor VIII:C-containing von Willebrand factor and the process relating thereto | |
| Winkelman et al. | Severely Heated Therapeutic Factor Vili Concentrate of High Specific Activity | |
| CN114787185B (zh) | 一种凝血因子ⅷ中间品的冻存方法 | |
| Wickerhauser et al. | Development of Large-Scale Fractionation Methods | |
| JPS59167519A (ja) | 不活化トロンビンゲルにより血漿タンパク質混合液からフイブリノ−ゲンを除去する方法 | |
| Smith et al. | Advances in Plasma Fractionation and in the Production of Factor VIII Concentrates | |
| EP0126789B1 (en) | Antihemophilic factor concentrate and process for its preparation | |
| Kang et al. | Intrinsic activation of prothrombin potentiated by celite and reduced by kaolin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| A85 | Still pending on 85-01-01 | ||
| BN | A decision not to publish the application has become irrevocable |